Tuberculosis

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed October 20, 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.⁸ Tuberculosis is curable, and the treatment is a full course of combination antibiotics taken for months. The single most important thing is completing it. Stopping early is how drug-resistant tuberculosis is created, and multidrug-resistant TB requires far longer, more toxic treatment with worse outcomes, for the patient and for everyone they subsequently infect. Nothing on this page treats tuberculosis, and there is no herbal alternative to consider. Two practical points that are genuinely nutritional. Pyridoxine (vitamin B6) is given alongside isoniazid to prevent peripheral neuropathy and is not optional. And TB causes severe wasting, so nutritional support during treatment is part of care rather than an add-on. Active pulmonary TB is contagious and reportable; contact tracing protects the people around you.

1. On latent versus active disease: latent tuberculosis infection means the organism is present and contained, with no symptoms and no infectiousness, and is treated to prevent reactivation, commonly with three months of weekly rifapentine and isoniazid or four months of rifampin. Active pulmonary tuberculosis is infectious and requires multidrug treatment, conventionally an intensive phase followed by a continuation phase. ↩
2. On adherence and resistance. Incomplete or irregular treatment selects for resistant organisms. Multidrug-resistant tuberculosis requires prolonged regimens with greater toxicity and lower cure rates, though newer all-oral regimens such as BPaL and BPaLM have substantially improved outcomes, and a trial-based analysis found them cost-saving for both patient and health system while cutting pill burden, PubMed 39890235. Directly observed therapy and other adherence support improve completion, and health departments provide treatment free of charge in many countries precisely because completion is a public health matter. ↩
3. On pyridoxine with isoniazid. Isoniazid interferes with vitamin B6 metabolism and causes peripheral neuropathy, and pyridoxine at around 25 to 50 mg daily is given routinely to prevent it, particularly in people with diabetes, HIV, alcohol use, malnutrition, kidney failure or pregnancy. This is a rare instance where a vitamin is part of the prescribed regimen rather than an optional extra. A 2026 review of anti-tuberculosis drug side effects gives 25 to 50 mg a day to prevent the nerve damage in higher-risk patients, and 50 to 100 mg a day to treat it once it appears, PubMed 41939271. ↩
4. On hepatotoxicity: isoniazid, rifampin and pyrazinamide are all potentially hepatotoxic, with isoniazid and rifampin the main contributors, and liver function is monitored on a schedule with defined thresholds for pausing treatment, PubMed 41939271. Alcohol should be avoided, and new nausea, vomiting, abdominal pain, dark urine or jaundice during treatment should prompt immediate contact with the treating team rather than stopping tablets unilaterally. ↩
5. On nutrition and tuberculosis: active tuberculosis causes profound catabolism and wasting, and undernutrition is both a risk factor for progression from infection to disease and a predictor of poor outcome. Nutritional support during treatment improves weight gain and, in trial evidence from high-burden settings, has been associated with better outcomes and reduced incidence among household contacts. This is one of the clearer nutrition-infection relationships in medicine. ↩
6. On vitamin D: vitamin D has a plausible role in macrophage antimycobacterial activity and deficiency is common in tuberculosis. Pooling individual data from eight randomized trials, vitamin D did not change time to sputum culture conversion overall, PubMed 30728208. It did accelerate conversion in the subgroup with multidrug-resistant disease, though that estimate rests on small numbers and its confidence interval is extremely wide, and no effect appeared in drug-sensitive tuberculosis. Vitamin D did modestly speed sputum smear conversion overall, a secondary outcome, and changed no other secondary outcome. This is a marker of how fast sputum clears, not a measure of cure. Correct deficiency; do not expect it to change the course of the disease. ↩
7. On who is most at risk: HIV co-infection is the strongest risk factor for progression, and everyone diagnosed with tuberculosis should be tested for HIV. Diabetes, silicosis, tumor-necrosis-factor inhibitors and other immunosuppressants, smoking, malnutrition and crowded living conditions all raise risk. Screening before starting immunosuppressive therapy is standard. ↩
8. National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic. ↩
9. On treating drug-susceptible tuberculosis: CDC recommends a 6-⁠month regimen of 2 months of isoniazid, rifampin, pyrazinamide and ethambutol followed by 4 months of isoniazid and rifampin. It also lists a 4-⁠month regimen of 2 months of isoniazid, rifapentine, pyrazinamide and moxifloxacin followed by 2 months and 1 week of isoniazid, rifapentine and moxifloxacin, a total of 17 weeks, CDC, 2025. ↩
10. On the 4-⁠month rifapentine regimen: in a phase 3 trial of 2,516 people with pulmonary tuberculosis in 13 countries, the regimen with rifapentine and moxifloxacin was noninferior to the standard 6-⁠month regimen, with an unfavorable outcome in 15.5% against 14.6%, PubMed 33951360. A 4-⁠month rifapentine regimen without moxifloxacin was not shown to be noninferior. ↩
11. On BPaL: in a single-group study of 109 patients with extensively drug-resistant tuberculosis, or multidrug-resistant tuberculosis that had not responded to or could not tolerate treatment, 26 weeks of oral bedaquiline, pretomanid and linezolid gave a favorable outcome in 90% at 6 months after treatment ended, PubMed 32130813. Linezolid side effects were common, peripheral neuropathy in 81% and myelosuppression in 48%, and often led to dose reductions or interruptions. ↩
12. On the global picture: WHO estimates that about a quarter of the world's population has been infected with TB bacteria and that about 5 to 10% of those infected eventually develop TB disease; that 10.7 million people fell ill with TB and 1.23 million died of it in 2024, making it the leading cause of death from a single infectious agent; that people living with HIV are 12 times more likely to fall ill with TB disease; and that of the new cases in 2024, an estimated 0.97 million were attributable to undernutrition, 0.93 million to diabetes, 0.74 million to alcohol use disorders and 0.70 million to smoking. It states that TB is preventable and curable, that medicines need to be taken daily for 4 to 6 months, that stopping early or without medical advice can make the bacteria resistant, that preventive treatment stops infection becoming disease, that the BCG vaccine protects children from serious forms of TB, and that since 2022 WHO guidelines have prioritized a 6-⁠month all-oral regimen for eligible people with multidrug-resistant TB, WHO, tuberculosis fact sheet. ↩
13. On contacts: a systematic review of 203 studies found latent infection in 51.5% of contacts of people with TB in low- and middle-income settings and 28.1% in high-income settings, with TB most likely to develop in the first year after exposure, PubMed 22936710. ↩
14. On cost and completion: New York City's health department offers free TB treatment at its clinics, with support to take medicine daily by video or in-person directly observed therapy, asks people to keep taking medicine until the provider says treatment is complete, and warns that stopping early can make the germs come back stronger and harder to treat; in England, treatment for most infectious diseases is free to everyone, including visitors from abroad, NYC Health, tuberculosis and NHS, services free to everyone. ↩
15. On the 3-⁠month weekly regimen for latent TB: in a trial of 7,731 people at high risk, 3 months of weekly directly observed treatment prevented TB as well as 9 months of daily self-administered treatment and was completed by 82.1% against 69.0%, with less liver toxicity (0.4% against 2.7%), PubMed 22150035. ↩
16. On what treatment involves: MedlinePlus states that the goal of treatment is to cure the infection with medicines, usually 4 at first, taken for 6 months or longer; that not taking them as instructed can make the bacteria resistant; that people may need to stay at home or in the hospital for 2 to 4 weeks until they are no longer contagious; that providers are required by law to report TB to the local health department; that symptoms often improve 2 to 3 weeks after starting treatment; and that TB medicines can cause side effects including vision changes and liver inflammation, so a vision test may be done before treatment starts to monitor any change, MedlinePlus, pulmonary tuberculosis. ↩
17. On TB medicines and other products: some medicines, including several HIV medicines, cannot be taken with the main rifamycin antibiotic used for TB and others need a dose change or extra monitoring, so any change needs a doctor's or pharmacist's advice first; the fluoroquinolone antibiotic used in some TB regimens is blocked by antacids and multivitamins containing magnesium, aluminum, zinc or iron, which should be taken at least 8 hours before or 4 hours after it; and both drug information pages advise keeping a written list of every vitamin, mineral and dietary supplement to show your clinicians, MedlinePlus drug information (rifamycin) and MedlinePlus drug information (fluoroquinolone). ↩
18. On N-acetylcysteine in TB: it is given to treat liver injury caused by TB drugs; in laboratory studies it boosted first- and second-line TB drugs, but in infected mice it did not add to their activity, PubMed 33619056. ↩
19. On nutrition in the RATIONS trial in India: food rations for household contacts of people with lung TB lowered new TB cases by 39% (all forms) to 48% (confirmed lung TB). Among the 2,800 patients, who all received rations alongside their TB treatment, a 5% weight gain in the first 2 months was linked with a lower risk of death, and diabetes with a higher one, PubMed 37567200 and PubMed 37567210. ↩
20. On symptoms, risk and emergencies: NHS guidance lists a cough lasting more than 3 weeks, tiredness, fever or night sweats, loss of appetite and weight loss as symptoms, and names people who spend a lot of time with someone with active TB, people born in or who lived where TB is more common, people with a weakened immune system such as from HIV, diabetes, a kidney transplant, chemotherapy or biologic medicines, children under 5, people who are homeless or in prison, and people who smoke, drink alcohol or take drugs as more likely to get it. It advises emergency care for a stiff neck with a severe headache, pain looking at bright lights, a seizure, sudden confusion or weakness in part of the body, which can mean TB has spread to the brain, and taking antibiotics, usually for at least 6 months, until the course is complete even after feeling better, NHS, tuberculosis. ↩
21. On coughing up blood: NHS guidance advises an urgent appointment for a few small spots, flecks or streaks of blood in the phlegm, and calling emergency services or going to the emergency department immediately for more than just a few spots or streaks of blood, or for coughing up blood with difficulty breathing, a very fast heartbeat or pain in the chest or upper back, NHS, coughing up blood. ↩
22. Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of long-term marine omega-⁠3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981-⁠1990. PubMed 34612056. Seven trials with 81,210 people followed for about 5 years: omega-⁠3 supplements were linked to a higher risk of atrial fibrillation (hazard ratio 1.25), more so in trials of more than 1 g a day (1.49), and the risk rose with each additional gram. ↩